Ekso Bionics (NASDAQ:EKSO) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Tuesday. The brokerage set a “hold” rating on the stock.

Several other analysts also recently weighed in on the company. Lake Street Capital dropped their price objective on Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Ekso Bionics in a research report on Tuesday, March 4th.

Ekso Bionics Price Performance

Shares of EKSO stock opened at $0.35 on Tuesday. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28. Ekso Bionics has a twelve month low of $0.34 and a twelve month high of $1.57. The company has a market cap of $8.69 million, a P/E ratio of -0.54 and a beta of 1.43. The business has a fifty day simple moving average of $0.60 and a 200 day simple moving average of $0.81.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.07). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The business had revenue of $5.09 million for the quarter, compared to the consensus estimate of $5.05 million. On average, sell-side analysts forecast that Ekso Bionics will post -0.48 EPS for the current fiscal year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.